Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.
about
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trialEffect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data.Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.Drug safety profile of integrase strand transfer inhibitors.Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q33629439-C24B0DF6-B728-4AF2-919E-B8CFE2F1A3D7Q33748099-0C6D90E8-136A-43CD-AFAB-7E590FD4DBD9Q33910849-B255AF1F-1031-49C2-830F-2C2C17FA1650Q36157703-27252C79-77DC-443C-ADC2-C1EF51AD8BCEQ36266898-9AF1002B-ED31-4815-837C-2024ADC229A3Q36311771-5A2CA82F-61CA-4B0E-8996-426371C0780BQ37653463-D16A4373-1856-4044-B882-7CED8DB1A9F7Q38193524-EB15A2C4-F103-44F7-81F6-C489FA60028AQ40706247-1FBD8AE7-1EE4-4B68-BDC0-65A85D7DEEFFQ56988548-36A2604A-156E-4C21-87FA-39F2C60D4B65Q57180790-19F36501-E45F-4DC3-B672-8CC84D7C5AE1
P2860
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@ast
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@en
type
label
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@ast
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@en
altLabel
Safety, tolerability, and effi ...... results from the REALMRK Study
@en
prefLabel
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@ast
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@en
P2093
P2860
P921
P356
P1476
Safety, tolerability, and effi ...... esults from the REALMRK Study.
@en
P2093
Anthony Rodgers
Bach-Yen T Nguyen
Benjamin Cheng
Beth E Jackson
Chengxing Lu
Farid Marquez
Juergen K Rockstroh
Karam Mounzer
Kathleen E Squires
Kim M Strohmaier
P2860
P304
P356
10.1089/AID.2012.0292
P407
P577
2013-02-26T00:00:00Z